Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Squamous Cell Cancer 2Recurrence 1Oropharyngeal Neoplasms 1Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Cisplatin 24pembrolizumab 23Magnetic Resonance Spectroscopy 19Specimen Handling 16Radiotherapy, Intensity-Modulated 12Carboplatin 12Cetuximab 111,2-diaminocyclohexaneplatinum II citrate 10Platinum 9Paclitaxel 9Radiotherapy 6Radiation 6Fluorouracil 6Biopsy 5Taxes 4Nivolumab 4Docetaxel 4(225)Ac-DOTA-c(RGDyK) 4X-Rays 3Pemetrexed 3Fluorodeoxyglucose F18 3reolysin 2pralsetinib 2ipatasertib 2cemiplimab 2atezolizumab 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy, Image-Guided 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Alpelisib × Head & Neck × Clear all
NCT02298595 2017-11-13

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

University of Pittsburgh

Phase 1/2 Withdrawn
Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡